| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/05/2002 | US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea |
| 12/05/2002 | US20020183343 Ultrashort-acting opioids for transdermal application |
| 12/05/2002 | US20020183341 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline |
| 12/05/2002 | US20020183336 Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists |
| 12/05/2002 | US20020183335 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| 12/05/2002 | US20020183334 For therapy of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder |
| 12/05/2002 | US20020183332 Substituting for the benzodiazepine in a patient in need thereof, a benzodiazepine withdrawal symptom alleviating effective dose of cyamemazine, or a pharmaceutically acceptable salt thereof |
| 12/05/2002 | US20020183331 For therapy of schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced psychoses or dyskinesias, Tourette's syndrome, hyperprolactinemia, or addiction to ethanol, nicotine, cocaine |
| 12/05/2002 | US20020183330 For therapy of schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced psychoses or dyskinesias, Tourette's syndrome, hyperprolactinemia, or addiction to ethanol, nicotine, cocaine |
| 12/05/2002 | US20020183329 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline |
| 12/05/2002 | US20020183327 For use as analgesics |
| 12/05/2002 | US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy |
| 12/05/2002 | US20020183322 Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline as 5-HT1A antagonists |
| 12/05/2002 | US20020183321 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 12/05/2002 | US20020183320 For use as analgesics |
| 12/05/2002 | US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer |
| 12/05/2002 | US20020183316 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders |
| 12/05/2002 | US20020183313 Cholecystokinin-A and B (CCK-A/B) antagonists and useful in therapy and prophylaxis of disorders of appetite regulatory systems (e.g., anorexia) disorders associated with intestinal smooth muscle hyperactivity (e.g., irritable bowel syndrome) |
| 12/05/2002 | US20020183312 Combination of cyamemazine and an atypical neuroleptic |
| 12/05/2002 | US20020183309 For therapy of acute myocardial infarction, asthma, bipolar disorder, cognitive enhancement, cognitive deficits in psychiatric disorders, cutaneous carcinoma, drug abuse, depression, gastrointestinal disorders, inflammation |
| 12/05/2002 | US20020183306 Combination treatment for sleep disorders including sleep apnea |
| 12/05/2002 | US20020183294 Therapy and prophylaxis of cognitive dysfunction in a human or non-human animal by administering sapogenin derivatives wherein the E and/or F ring of the fused ring system has been cleaved |
| 12/05/2002 | US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 12/05/2002 | US20020183281 For therapy and prophylaxis of disorders that are ameliorated by the inhibition of neuronal monoamine uptake in mammals; disorders including erectile dysfunction, affective disorders, obesity, cerebral function disorders, pain |
| 12/05/2002 | US20020183269 Novel compounds |
| 12/05/2002 | US20020183263 Nutritional preparation comprising ribose and medical use thereof |
| 12/05/2002 | US20020183250 For use in therapy of sleep disorders |
| 12/05/2002 | US20020182698 Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| 12/05/2002 | US20020182691 Nucleotide sequences coding transport protein for use in nervous system disorders |
| 12/05/2002 | US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders |
| 12/05/2002 | US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders |
| 12/05/2002 | US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect |
| 12/05/2002 | US20020182278 Composition containing Asiasari Radix extracts for protecting brain cells and improving memory |
| 12/05/2002 | US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance |
| 12/05/2002 | US20020182247 Patches containing buprenorphine hydrochloride |
| 12/05/2002 | US20020182219 Cancer immunotherapy |
| 12/05/2002 | US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. |
| 12/05/2002 | US20020182213 Method for the treatment of fibrosis |
| 12/05/2002 | US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/05/2002 | US20020182201 Matrix stabilized enzyme crystals and methods of use |
| 12/05/2002 | US20020182198 Purified MANF polypeptide (mature astrocyte-derived neurotrophic factor) of given sequence |
| 12/05/2002 | DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases |
| 12/05/2002 | DE10118282A1 Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and tackifier resins, for medical uses |
| 12/05/2002 | CA2750876A1 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 5-carboxamide |
| 12/05/2002 | CA2665748A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 12/05/2002 | CA2459176A1 Oral composition comprising an extract from the bark of albizzia myriophylla |
| 12/05/2002 | CA2455341A1 Novel ligand for nicotinic acetylcholine receptors useful in therapy |
| 12/05/2002 | CA2449979A1 A method of purification of neural stem cells |
| 12/05/2002 | CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 12/05/2002 | CA2449118A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 12/05/2002 | CA2449056A1 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| 12/05/2002 | CA2449019A1 Method for treating nerve injury caused by surgery |
| 12/05/2002 | CA2449017A1 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore |
| 12/05/2002 | CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins |
| 12/05/2002 | CA2448956A1 Anti-ngf antibodies for the treatment of various disorders |
| 12/05/2002 | CA2448894A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 12/05/2002 | CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin |
| 12/05/2002 | CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production |
| 12/05/2002 | CA2448567A1 Modulators of nucleic acid ligands |
| 12/05/2002 | CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| 12/05/2002 | CA2448362A1 B7 related protein-2 molecules and uses thereof |
| 12/05/2002 | CA2448306A1 Method for treating fibrotic diseases or other indications |
| 12/05/2002 | CA2448294A1 Method for treating fibrotic diseases or other indications vi |
| 12/05/2002 | CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases |
| 12/05/2002 | CA2448246A1 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| 12/05/2002 | CA2448205A1 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor |
| 12/05/2002 | CA2448198A1 5-substituted-2-arylpyridines as crf1 modulators |
| 12/05/2002 | CA2448171A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 12/05/2002 | CA2448160A1 Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
| 12/05/2002 | CA2448148A1 Carbohydrate-associated proteins |
| 12/05/2002 | CA2448146A1 Secreted proteins |
| 12/05/2002 | CA2448116A1 Molecules for disease detection and treatment |
| 12/05/2002 | CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 12/05/2002 | CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 12/05/2002 | CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments |
| 12/05/2002 | CA2447884A1 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| 12/05/2002 | CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 12/05/2002 | CA2447662A1 Transporters and ion channels |
| 12/05/2002 | CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 12/05/2002 | CA2447234A1 Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases |
| 12/05/2002 | CA2446723A1 Antibodies that immunospecifically bind to trail receptors |
| 12/05/2002 | CA2446532A1 Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression |
| 12/05/2002 | CA2443713A1 Proteins associated with cell growth, differentiation, and death |
| 12/05/2002 | CA2443350A1 Ultrashort-acting opioids for transdermal application |
| 12/05/2002 | CA2443346A1 Anticholinergic compounds and methods of use |
| 12/04/2002 | EP1262198A1 Composition with sustained release of levodopa and carbidopa |
| 12/04/2002 | EP1262197A2 Combination treatment for sleep disorders including sleep apnea |
| 12/04/2002 | EP1262196A2 Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence |
| 12/04/2002 | EP1262188A1 Improved neuronal gene transfer |
| 12/04/2002 | EP1262184A1 Compositions comprising S-tofisopam and use of these compositions for the preparation of a medicament for the treatment or prevention of convulsions or seizures |
| 12/04/2002 | EP1262182A2 Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine |
| 12/04/2002 | EP1261744A2 Estrogen receptor beta variants and methods of detection thereof |
| 12/04/2002 | EP1261712A2 Proteins named fctrx and nucleic acids encoding same |
| 12/04/2002 | EP1261694A2 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 12/04/2002 | EP1261643A1 Composition for inhibiting macrophage activity |
| 12/04/2002 | EP1261638A2 Human fgf-23 gene and gene expression products |
| 12/04/2002 | EP1261636A2 Human protein kinases and protein kinase-like enzymes |
| 12/04/2002 | EP1261635A1 Human polynucleotides, polypeptides, and antibodies |
| 12/04/2002 | EP1261610A2 Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production |
| 12/04/2002 | EP1261609A1 Triazolotriazinones and the use thereof |